Literature DB >> 24238714

Leaving buprenorphine treatment: patients' reasons for cessation of care.

Jan Gryczynski1, Shannon Gwin Mitchell2, Jerome H Jaffe3, Kevin E O'Grady4, Yngvild K Olsen5, Robert P Schwartz2.   

Abstract

Many opioid-dependent patients leave treatment prematurely. This study is a planned secondary analysis from a randomized trial of counseling for African Americans (N=297) entering buprenorphine treatment at one of two outpatient programs. This study examines: (1) whether patients' initial treatment duration intentions prospectively predict retention; and (2) patients' reasons for leaving treatment. Participants were queried about their treatment duration intentions at treatment entry, and their reasons for leaving treatment at 6-month follow-up. At baseline, 28.0% reported wanting to stay in buprenorphine treatment less than 6 months, while 42.1% actually left buprenorphine treatment within 6 months. However, participants intending short-term buprenorphine at the outset were not at elevated risk of early treatment discontinuation (OR=1.15; p=.65). Participants attributed treatment cessation predominantly to conflicts with staff, involuntary discharge, and perceived inflexibility of the program. Future research should examine patient-centered models of buprenorphine treatment that could improve retention.
© 2014.

Entities:  

Keywords:  Buprenorphine; Dropout; Opioid dependence; Patient intentions; Retention

Mesh:

Substances:

Year:  2013        PMID: 24238714      PMCID: PMC3947058          DOI: 10.1016/j.jsat.2013.10.004

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  27 in total

1.  Factors associated with methadone maintenance treatment retention among street-recruited injection drug users.

Authors:  Robert E Booth; Karen F Corsi; Susan K Mikulich-Gilbertson
Journal:  Drug Alcohol Depend       Date:  2004-05-10       Impact factor: 4.492

Review 2.  Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies.

Authors:  Louisa Degenhardt; Chiara Bucello; Bradley Mathers; Christina Briegleb; Hammad Ali; Matt Hickman; Jennifer McLaren
Journal:  Addiction       Date:  2010-11-04       Impact factor: 6.526

3.  Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime.

Authors:  Jan Gryczynski; Timothy W Kinlock; Sharon M Kelly; Kevin E O'Grady; Michael S Gordon; Robert P Schwartz
Journal:  Subst Abus       Date:  2012       Impact factor: 3.716

4.  Premature discharge from methadone treatment: patient perspectives.

Authors:  Heather Schacht Reisinger; Robert P Schwartz; Shannon Gwin Mitchell; James A Peterson; Sharon M Kelly; Kevin E O'Grady; Erica A Marrari; Barry S Brown; Michael H Agar
Journal:  J Psychoactive Drugs       Date:  2009-09

5.  Redefining retention: recovery from the patient's perspective.

Authors:  Shannon Gwin Mitchell; Rika Morioka; Heather Schacht Reisinger; James A Peterson; Sharon M Kelly; Michael H Agar; Barry S Brown; Kevin E O'Grady; Robert P Schwartz
Journal:  J Psychoactive Drugs       Date:  2011 Apr-Jun

6.  "Should I stay or should I go?" Coming off methadone and buprenorphine treatment.

Authors:  Adam R Winstock; Nicholas Lintzeris; Toby Lea
Journal:  Int J Drug Policy       Date:  2010-10-16

7.  Incarceration and opioid withdrawal: the experiences of methadone patients and out-of-treatment heroin users.

Authors:  Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Robert P Schwartz
Journal:  J Psychoactive Drugs       Date:  2009-06

Review 8.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

9.  Ten-year follow-up after admission to methadone maintenance.

Authors:  J F Maddux; D P Desmond
Journal:  Am J Drug Alcohol Abuse       Date:  1992       Impact factor: 3.829

10.  Exposure to opioid maintenance treatment reduces long-term mortality.

Authors:  Amy Gibson; Louisa Degenhardt; Richard P Mattick; Robert Ali; Jason White; Susannah O'Brien
Journal:  Addiction       Date:  2008-01-08       Impact factor: 6.526

View more
  40 in total

Review 1.  Retention in medication-assisted treatment for opiate dependence: A systematic review.

Authors:  Christine Timko; Nicole R Schultz; Michael A Cucciare; Lisa Vittorio; Christina Garrison-Diehn
Journal:  J Addict Dis       Date:  2015-10-14

2.  Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.

Authors:  Babak Tofighi; Arthur Robin Williams; Chemi Chemi; Selena Suhail-Sindhu; Vicky Dickson; Joshua D Lee
Journal:  Subst Use Misuse       Date:  2019-08-20       Impact factor: 2.164

3.  Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program.

Authors:  Zoe M Weinstein; Gabriela Gryczynski; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong W Kim; Colleen Labelle; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2018-06-19       Impact factor: 4.492

4.  Linkage to Primary Care for Persons First Receiving Injectable Naltrexone During Inpatient Opioid Detoxification.

Authors:  Michael D Stein; Megan M Risi; Genie L Bailey; Bradley J Anderson
Journal:  J Subst Abuse Treat       Date:  2016-02-23

5.  Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?

Authors:  Angélica Meinhofer; Arthur Robin Williams; Phyllis Johnson; Bruce R Schackman; Yuhua Bao
Journal:  J Subst Abuse Treat       Date:  2019-07-24

6.  Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance Therapy.

Authors:  Brandon S Bentzley; Kelly S Barth; Sudie E Back; Garrett Aronson; Sarah W Book
Journal:  J Subst Abuse Treat       Date:  2015-04-07

7.  Long-term retention in Office Based Opioid Treatment with buprenorphine.

Authors:  Zoe M Weinstein; Hyunjoong W Kim; Debbie M Cheng; Emily Quinn; David Hui; Colleen T Labelle; Mari-Lynn Drainoni; Sara S Bachman; Jeffrey H Samet
Journal:  J Subst Abuse Treat       Date:  2016-12-30

8.  A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.

Authors:  Ned J Presnall; D A Patterson Silver Wolf; Derek S Brown; Sara Beeler-Stinn; Richard A Grucza
Journal:  J Subst Abuse Treat       Date:  2019-06-15

9.  Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.

Authors:  Hillary Samples; Arthur Robin Williams; Mark Olfson; Stephen Crystal
Journal:  J Subst Abuse Treat       Date:  2018-09-07

10.  Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality.

Authors:  Alex K Gertner; Allison G Robertson; Byron J Powell; Hendree Jones; Pam Silberman; Marisa Elena Domino
Journal:  Health Aff (Millwood)       Date:  2020-08       Impact factor: 6.301

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.